Viewing nowDiotan Tablet 80 mg (Valsartan)
Valsartan 80mg
Tablet · Prescription medication
Ilhwa Co., Ltd.

MFDS item code 200809258 · Notified 2008.09.05 · Insurance code 640901440
Treatment of hypertension and heart failure; reduction in the risk of death after myocardial infarction
This medication effectively helps control blood pressure in patients with essential hypertension. It is also used for the treatment of heart failure in patients unable to use ACE inhibitors, specifically those classified as NYHA stage II to IV. It is effective in reducing mortality risk in clinically stable patients exhibiting left ventricular dysfunction after a myocardial infarction. Thus, this medication plays an important role in managing hypertension, supporting heart failure control, and recovery after myocardial infarction, improving the health condition of patients.
1. Essential hypertension Take with water during a meal or between meals. It is recommended to take the medicine at the same time each day (e.g., in the morning), if possible. 1) Adults: The recommended dose is 80 mg of valsartan orally once daily, regardless of sex or race. The blood pressure-lowering effect develops gradually within 2 weeks and reaches its maximum after 4 weeks. For patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg daily or a diuretic may be coadministered. If additional blood pressure reduction is needed, the dose may be increased to a maximum of 320 mg daily. 2) Elderly patients (aged 75 years and older): Initiate treatment with 40 mg of this medicine once daily. 3) Patients with renal impairment: (1) Creatinine clearance 20 ∼ 50 mL/min: No dose adjustment is necessary. (2) Creatinine clearance 10 ∼ 20 mL/min: Initiate treatment with 40 mg of this medicine once daily. (3) Creatinine clearance below 10 mL/min and patients on dialysis: Do not administer this medicine. 4) Patients with volume depletion: In patients with volume depletion (e.g., patients taking high doses of diuretics whose dose cannot be reduced), initiate treatment with 40 mg of this medicine once daily. 5) Patients with hepatic impairment: In patients with mild to moderate hepatic impairment, initiate treatment with 40 mg of this medicine once daily; do not exceed 80 mg daily. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended starting dose is 40 mg of this medicine orally twice daily. The dose may be increased to 80 mg or 160 mg per dose. When administered concomitantly with a diuretic, consider reducing the diuretic dose. The maximum daily dose is 320 mg, administered in divided doses. Triple combination therapy with this medicine, an ACE inhibitor, and a beta-blocker is not recommended. 3. Reduction of the risk of death after myocardial infarction Adults: Treatment may be initiated within 12 hours of the onset of myocardial infarction. The recommended starting dose is 20 mg of this medicine twice daily. Thereafter, over several weeks, increase the dose as tolerated by the patient to 40 mg, 80 mg, and 160 mg per dose, administered twice daily. Consider dose reduction if symptoms of hypotension or renal failure occur. This medicine may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytic agents, acetylsalicylic acid, beta-blockers, and statins). However, concomitant use with an ACE inhibitor is not recommended. 4. Patients with renal impairment: No dose adjustment is necessary when creatinine clearance is 10 mL/min or higher. However, do not administer this medicine to patients with creatinine clearance below 10 mL/min or to patients on dialysis, as there is no experience with its use in these patients. 5. Patients with hepatic impairment: In patients with mild to moderate hepatic impairment, it is preferable not to exceed a daily dose of 80 mg. If administering 80 mg or more daily, consider whether the benefits of dose escalation outweigh the risks. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis.
Children and adolescents under 18 years of age: Safety and efficacy have not been established. Children and adolescents under 18 years of age: Safety and efficacy have not been established.
This medication can cause serious harm to the fetus if taken during pregnancy, especially in the second and third trimesters; thus, it should be discontinued immediately upon confirmation of pregnancy. Patients who have an allergic reaction to this medication, or those with severely impaired liver or kidney function, as well as pregnant or nursing women, should not take this medication. Elderly patients, those with high serum potassium levels, and patients with mild hepatic impairment should take caution while using this medication and may require dosage adjustments. This medication has blood pressure-lowering effects, so patients should be closely monitored for symptoms of hypotension when beginning treatment or increasing the dose. Patients with heart failure or recent myocardial infarction should have their kidney function monitored periodically, and caution should be exercised for potential interactions when taking this medication with other antihypertensive drugs. During treatment, side effects such as headache, dizziness, fatigue, and cough may occur; patients should consult healthcare professionals if unusual symptoms appear. There is a risk of dangerously high serum potassium levels if taken with potassium-sparing diuretics or potassium supplements, so caution is needed. Regular blood tests to check for abnormalities, such as liver function tests or kidney function tests, are advisable. This medication has not established safety and effectiveness in children and adolescents, so its use is discouraged. In case of overdose, severe hypotension or altered consciousness may occur, necessitating immediate medical attention. When storing, keep this medication in a place out of reach of children and do not transfer it to another container, as this is safer. Dizziness may occur when driving or operating machinery, so caution is advised. Women who are pregnant or planning to become pregnant should consult healthcare professionals before taking this medication, and breastfeeding mothers are also advised to avoid its use.
Not everyone experiences these, and they can vary from person to person.
This medication is sensitive to air and moisture and should be stored in a sealed container. Additionally, it is important to store it in a cool place below 30 degrees Celsius to maintain its effectiveness.
Pale red round film-coated tablet
30 tablets/bottle, 100 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowValsartan 80mg
Tablet · Prescription medication
Ilhwa Co., Ltd.

Valsartan 80mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.

Valsartan 160mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.

Valsartan 40mg
Tablet · Prescription medication
Samsung Novartis Co., Ltd.
Valsartan
Prescription medication
Korea Sandos Co., Ltd.
Valsartan
Prescription medication
Korea Sandos Co., Ltd.

Valsartan
Prescription medication
Korea Sandos Co., Ltd.

Valsartan 320mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.